WO2012069416A1 - Oligosaccharide mixture and food product comprising this mixture, especially infant formula - Google Patents
Oligosaccharide mixture and food product comprising this mixture, especially infant formula Download PDFInfo
- Publication number
- WO2012069416A1 WO2012069416A1 PCT/EP2011/070566 EP2011070566W WO2012069416A1 WO 2012069416 A1 WO2012069416 A1 WO 2012069416A1 EP 2011070566 W EP2011070566 W EP 2011070566W WO 2012069416 A1 WO2012069416 A1 WO 2012069416A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food product
- oligosaccharide
- food
- mixture
- lacto
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 123
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 122
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 235000013305 food Nutrition 0.000 title claims abstract description 64
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 33
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 claims abstract description 18
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 claims abstract description 18
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 24
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 24
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 24
- 235000016709 nutrition Nutrition 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 17
- 230000007815 allergy Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 13
- 235000020932 food allergy Nutrition 0.000 claims description 13
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 12
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 12
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 9
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 9
- 239000013566 allergen Substances 0.000 claims description 8
- 235000020244 animal milk Nutrition 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 8
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 7
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 7
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 7
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 7
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 claims description 7
- 208000004998 Abdominal Pain Diseases 0.000 claims description 6
- 206010016946 Food allergy Diseases 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 235000008452 baby food Nutrition 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 claims description 4
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 230000008821 health effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 3
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 3
- 208000002881 Colic Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- GKEWHGPIQCSUCC-JJGOEJEFSA-N Monofucosyllacto-N-hexaose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)C[C@@H](OO[C@@H]2[C@@H]([C@H](O[C@H]3[C@@H](C(O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O2)O)[C@@H]1NC(C)=O GKEWHGPIQCSUCC-JJGOEJEFSA-N 0.000 claims description 3
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- RQNFGIWYOACERD-UHFFFAOYSA-N lacto-N-Difucosylhexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O RQNFGIWYOACERD-UHFFFAOYSA-N 0.000 claims description 3
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 235000020209 toddler milk formula Nutrition 0.000 claims description 3
- BCUMESVDMXHZRL-UHFFFAOYSA-N difucosyllacto-n-hexaose i Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(C(NC(C)=O)C(OC4C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C4O)O)OC3CO)OC3C(C(O)C(O)C(C)O3)O)OC(CO)C2O)O)OC1CO BCUMESVDMXHZRL-UHFFFAOYSA-N 0.000 claims description 2
- 229930193965 lacto-N-fucopentaose Natural products 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims 1
- 230000003116 impacting effect Effects 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 19
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 18
- 235000013406 prebiotics Nutrition 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 235000020256 human milk Nutrition 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 210000004251 human milk Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229940062827 2'-fucosyllactose Drugs 0.000 description 9
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 description 9
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 7
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241001608472 Bifidobacterium longum Species 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- -1 3-fucosullactose Chemical compound 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 241001112696 Clostridia Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000774 hypoallergenic effect Effects 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000004977 Hueckel calculation Methods 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000020218 follow-on milk formula Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 1
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 235000019904 Raftiline® Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002574 ketohexoses Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Oligosaccharide mixture and food product comprising
- the invention relates to an oligosaccharide mixture and to a food product comprising said oligosaccharide mixture, especially infant formula, Background of the invention
- the human colon is colonised by a wide range of bacteria having both positive and negative effects on the gut's physiology, as well as having other systemic influences.
- the predominant groups of bacteria found in the colon include Bacteroides species, in particular Bifidobacteria, Eubacteria, Clostridia and Lactobacilli. These bacteria have fluctuating activities in response to substrate availability, redox potential, pH , 0 2 tension and their distribution in the colon.
- Bacteroides species in particular Bifidobacteria, Eubacteria, Clostridia and Lactobacilli. These bacteria have fluctuating activities in response to substrate availability, redox potential, pH , 0 2 tension and their distribution in the colon.
- intestinal bacteria can be divided into species exerting either potentially harmful or beneficial effects on their host.
- Pathogenic effects (which may be caused by Clostridia or Bacteroides, for example) include diarrhoea, infections, liver damage, carcinogenesis and intestinal putrefaction.
- Health-promoting effects may be induced through the inhibition of the growth of harmful bacteria, the stimulation of immune functions, improvements in the digestion and absorption of essential nutrients and the synthesis of vitamins.
- An increase in the numbers and/or activities of bacterial groups (such as Bifidobacteria and Lactobacilli) that may have health promoting properties is desirable.
- the faecal flora of breast-fed infants includes appreciable populations of bifidobacteria with some Lactobacillus species, whereas formula-fed infants have more complex microbiota, with Bifidobactera species and Bacteroides species, Clostridia and Streptococci being usually present.
- a prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, thereby improving the host's health.
- Such ingredients are non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine and thus pass intact to the colon where they are selectively fermented by the beneficial bacteria.
- prebiotics include certain oligosaccharides, such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS),
- indigestible oligosaccharides represent the third largest solid component (after lactose and lipids) in breast milk, occurring at a concentration of 12-15 g/l i n colostrum and 5-8 g/l in mature milk.
- Human milk oligosaccharides are highly resistant to enzymatic hydrolysis, indicating that these oligosaccharides may display essential functions not directly related to their caloric value.
- E P 0 975 235 B1 from Abbott Laboratories describes a synthetic nutritional composition comprising one or more human milk oligosaccharides, wherein the HMOs in the composition are chosen among a group of eight HMOs (3-fucosyllactose, lacto- N-fucopentaose I I I , lacto-N-fucopentaose II, difucosyllactose, 2'-fucosyllactose, lacto- N-fucopentaose I , lacto-N-neotetraose and lacto-N-fucopentaose V) wherein said composition is intended for cases of normal, healthy infants, children, adults or subjects having specialized needs such as those that accom pany certain pathological conditions.
- An object of the present invention is to provide a food product which is effective as a prebiotic, particularly in the human gut. There is a need for a food product, especially targeted at babies, infants and/or new born infants that help securing a normal immune or inflammation status or mitigate or reduce the effect of food allergies.
- the present invention provides an oligosaccharide mixture comprising at least one N- acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide.
- the above mixture of ingredients is a new protective and immuno-modulating composition that is particularly effective as a prebiotic in a food product.
- the mixture is structurally closer to human breast milk oligosaccharides than commercially available prebiotic ingredients, such as FOS and GOS, due to the fact it comprises, for example, a mixture of specific acidic (sialylated) and neutral (fucosylated or N-acetyl- lactosamine) oligosaccharides.
- the oligosaccharide mixture may be derived from animal milk, such as one or more of cow, goat or buffalo milk.
- the oligosaccharide mixture is a synthetic composition.
- the invention relates to a food product comprising an oligosaccharide mixture as described above.
- the food product is proposed as infant food or formula, but the product may be used in any food or drink consumed by babies, infants or adults.
- Adults usually use the oligosaccharide mixture according to the invention when needed, in particular in the technical field of clinical nutrition. Consumption of a food product containing such an oligosaccharide mixture as a prebiotic will selectively promote the growth and/or activity of one or a limited number of beneficial bacteria in the colon, and will thus improve the host's health.
- infant means a child under the age of 12 months.
- young child means a child aged between one and three years.
- infant formula means a foodstuff intended for particular nutritional use by infants during the first four to six months of life and satisfying by itself the nutritional requirements of this category of person (Article 1 .2 of the European Commission Directive 91/321/EEC of May 14, 1991 on infant formulae and follow-on formulae).
- follow-on formula means a foodstuff intended for particular nutritional use by infants aged over four months and constituting the principal liquid element in the progressively diversified diet of this category of person.
- starter infant formula means a foodstuff intended for particular nutritional use by infants during the first four months of life.
- baby food means a foodstuff intended for particular nutritional use by infants during the first years of life.
- infant cereal composition means a foodstuff intended for particular nutritional use by infants during the first years of life.
- growing-up milk means a milk-based beverage adapted for the specific nutritional needs of young children.
- the term "nutritional composition” means a composition which nourishes a subject. This nutritional composition is usually to be taken orally or intraveinously, and it usually includes a lipid or fat source and a protein source.
- synthetic composition means a composition obtained by chemical and/or biological (e.g. enzymes) means, which can be chemically identical to the mixture naturally occurring in mammalian milks. A composition is said to be synthetic as soon as at least one of its components is obtained by chemical and/or biological (e.g. enzymatic) means.
- hypoallergenic composition means a composition which is unlikely to cause allergic reactions.
- sialylated oligosaccharide means an oligosaccharide having a sialic acid residue.
- oligosaccharide means an oligosaccharide having a fucose residue.
- prebiotic means non-digestible carbohydrates that beneficially affect the host by selectively stimulating the growth and/or the activity of healthy bacteria such as bifidobacteria in the colon of humans (Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401-12).
- probiotic means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host.
- An “allergy” is an allergy which has been detected by a medical doctor and which can be treated occasionally or in a more durable manner.
- a “food allergy” is an allergy with respect to a nutritional composition.
- the oligosaccharide mixture according to the invention is preferably a hypoallergenic composition.
- the invention provides an oligosaccharide mixture which comprises at least one N- acetyl-lactosamine selected from the group comprising lacto-N-tetraose and lacto-N- neotetraose, at least one sialylated oligosaccharide selected from the group comprising 3'-sialyllactose and 6'-sialyllactose, and at least one fucosylated oligosaccharide s e l e cte d f ro m th e g ro u p co m p ri s i n g 2'-fucosyl lactose, 3-fucosullactose, difucosyllactose, lacto-N-fucopentaoses (that is to say lacto-N-fucopentaose I, lacto-N- fucopentaose I
- the oligosaccharide mixture according to the invention when comprised in a food product, is particularly advantageous for preventing and reducing the risk and/or reducing the severity and/or reducing the occurrence of food allergies and related food allergy effects on health.
- Said effects are preferably (i) skin effects, atopic dermatitis, rash, or redness ; (ii) effects on the immune system or inflammation status ; or (iii) effects on the gastro-intestinal system such as colics, abdominal pain and the like.
- the oligosaccharide mixture of the invention may be derived from animal milks.
- the milk may be obtained from any mammal, in particular from cows, goats, buffalos, horses, elephants, camels or sheep.
- Said oligosaccharide mixture contains at least one N-acetyl-lactosamine. That is to say that it contains N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl- lactosamine.
- Suitable oligosaccharides containing N-acetyl-lactosamine include lacto- N-tetraose (LNT) and lacto-N-neotetraose (LNnT).
- the N-acetyl-lactosamine is preferably selected from the group comprising lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).
- LNT and LNnT may be synthesised chemically by enzymatic transfer of saccharide units from donor moieties to acceptor moieties using glycosyltransferases as described for example in US patent No. 5,288,637 and WO 96/10086.
- LNT and LNnT may be prepared by chemical conversion of Keto-hexoses (e.g. fructose) either free or bound to an oligosaccharide (e.g. lactulose) into N-acetylhexosamine or an N- acetylhexosamine-containing oligosaccharide as described in Wrodnigg, T.M. ; Stutz, A.E. (1999) Angew. Chem.
- Keto-hexoses e.g. fructose
- an oligosaccharide e.g. lactulose
- N-acetyl-lactosamine produced in this way may then be transferred to lactose as the acceptor moiety.
- the oligosaccharide mixture according to the invention contains from 0.1 to 3g N-acetyl-lactosamine lactose(s)/1 OOg oligosaccharide mixture on a dry weight basis.
- DP degree of polymerisation
- the oligosaccharide mixture according to the invention contains from 0.05 to 2 g , more preferably 0. 1 to 2g , of sialylated ol igosaccharide(s) per 1 00g of oligosaccharide mixture on a dry weight basis.
- the fucosylated oligosaccharide may be selected from the group comprising 2'- fucosyllactose, 3-fucosyllactose, difucosyllactose, lacto-N-fucopentaose I , lacto-N- fucopentaose I I , l acto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N- difucohexaose I , monofucosyllacto-N-hexaose, Difucosyllacto-N-h exao se I a n d Difucosyllacto-N-neohexaose II.
- a particularly preferred fucosylated oligosaccharide is 2'-fucosyllactose.
- the fucosylated oligosaccharide may be isolated by chromatography or filtration technology from a natural source such as animal milks. Alternatively, it may be produced by biotechnological means using specific fucosyltransferases and/or fucosidase eithe r th roug h th e u se of enzym e-based fermentation technology (recombinant or natural enzymes) or microbial fermentation technology. In the latter case, microbes may either express their natural enzymes and substrates or may be engineered to produce respective substrates and enzymes. Single microbial cultures and/or mixed cultures may be used.
- fucosylated oligosaccharides may be produced by chemical synthesis from lactose and free fucose. Fucosylated oligosaccharides are also available for example from Kyowa, Hakko, Kogyo of Japan.
- the oligosaccharide mixture according to the invention contains from 0.1 to 3g of fucosylated oligosaccharide(s) per 100g of oligosaccharide mixture on a dry weight basis.
- the oligosaccharide mixture of the invention comprises f ro m 0 . 05 to 3 g o f th e to ta l a m o u n t o f N-acetyl-lactosamine(s), sialylated oligosaccharide(s) and fucosylated oligosaccharide(s) per 100g of oligosaccharide mixture.
- the oligosaccharide mixture described above is incorporated into a food product.
- the term "food product” is intended to encompass any consumable substance. Hence, it may be a product intended for consumption by humans, in particular an infant formula, a follow- up formula, infant or young children food such as infant cereals, and the like.
- the oligosaccharide mixtures of the invention can be incorporated into infant formulas, dehydrated milk or cereal mixtures.
- the invention also includes a food product comprising the oligosaccharide mixture of the invention.
- Said food product preferably comprises a protein source, a fat source and a carbohydrate source.
- the food product according to the invention is preferably a hypoallergenic composition.
- the food product according to the invention also contains a protein source.
- the type of protein is not believed to be critical to the present invention provided that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
- protein sources based on whey, casein and mixtures thereof may be used as well as protein sources based on soy.
- the protein source preferably comprises between 20% and 95% of whey proteins and/or proteins derived from whey.
- the protein source may be based on acid whey or sweet whey or mixtures thereof and may include alpha-lactalbumin and beta- lactoglobulin in any desired proportions.
- the food product according to the present invention generally contains a carbohydrate source. This is particularly preferable in the case where the food product of the invention is an infant formula.
- any carbohydrate source conventionally found in infant formulae such as lactose, saccharose, maltodextrin, starch and mixtures thereof may be used although the preferred source of carbohydrates is lactose.
- the food product according to the present invention generally contains a source of lipids. This is particularly relevant if the food product of the invention is an infant formula.
- the lipid source may be any lipid or fat which is suitable for use in infant formulae.
- Preferred fat sources include palm oleic, high oleic sunflower oil and high oleic safflower oil.
- the essential fatty acids linoleic and a-linolenic acid may also be added as may small amounts of oils containing high quantities of preformed arachidonic acid and docosahexaenoic acid such as fish oils or microbial oils.
- the fat source preferably has a ratio of n-6 to n-3 fatty acids of about 5: 1 to about 15: 1 ; for example about 8: 1 to about 10:1.
- the food product of the invention also contains preferably all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals.
- minerals, vitamins and other nutrients optionally present in the food product of the invention include vitamin A, vitamin B1 , vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form. The presence and amounts of specific minerals and other vitamins will vary depending on the intended population.
- the food product of the invention may contain emulsifiers and stabilisers such as soy, lecithin, citric acid esters of mono- and di-glycerides, and the like.
- the food product of the invention may also contain other substances which may have a beneficial effect such as lactoferrin, nucleotides, nucleosides, and the like.
- the food product according to the invention is preferably a synthetic nutritional composition.
- it can be a starter infant formula, an infant formula, a baby food, an infant cereal composition, a follow-on formula or a growing-up milk, and said food product is preferably a starter infant formula.
- the food product of the invention can further comprise at least one probiotic bacterial strain, said probiotic bacterial strain preferably being Bifidobacteria and/or Lactobacilli. Said food product is particularly advantageous for the enhancement of the oral tolerance to allergens.
- Suitable probiotic bacterial strains include Lactobacillus rhamnosus ATCC 53103 available from Valio Oy of Finland under the trademark LGG, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus paracasei CNCM 1-21 16, Lactobacillus reuteri sold by BioGaia A.
- the food product of the invention can further comprise at least one prebiotic, usually in an amount between 0.3 and 10% by weight of food product.
- the food product can also comprise prebiotics other than the N-acetyl- lactosamine, the sialylated oligosaccharide, and the fucosylated oligosaccharide according to the inveniton.
- prebiotics are usually non-digestible in the sense that they are not broken down and absorbed in the stomach or small intestine and thus remain intact when they pass into the colon where they are selectively fermented by the beneficial bacteria.
- prebiotics include certain oligosaccharides, such a fructooligosaccharides (FOS) and galactooligosaccharides (GOS).
- a parti cul arly preferred com bi nation of prebiotics is 70% short cha i n fructooligosaccharides and 30% inulin, which is a product sold by BENEO-Orafti under the trademark "Prebio 1".
- the food product according to the invention is preferably, for use in preventing and reducing the risk and/or reducing the severity and/or reducing the occurrence of food allergies and related food allergy effects on health.
- Said effects are preferably (i) skin effects, atopic dermatitis, rash, or redness ; (ii) effects on the immune system or inflammation status ; or (iii) effects on the gastro-intestinal system such as colics, abdominal pain and the like.
- composition according to the invention can further comprise other nutritional compounds that synergize with the claimed oligosaccharides to deliver the claimed benefits on skin, such as skin allergies or atopic dermatitis.
- additional compounds can be for example specific non-hydrolyzed proteins, low allergenic proteins (i.e. hydrolyzed or partly hydrolyzed proteins), low lactose ingredients, low lactose saccharides or hydrolyzed saccharides. It is postulated that the synergy of the ingredients may be established by the fact that the ingredients all together help to maintain a low physiological level of an effector that stays below threshold where skin effects (such as atopic dermatitis) starts to show.
- the food product according to the invention is for use in the enhancement of the oral tolerance to allergens.
- the invention is also related to the use of a food product comprising an oligosaccharide mixture com prising of at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and least one fucosylated oligosaccharide, as a synthetic nutritional composition (i.e. as a synthetic nutritional agent), for preventing and reducing the risk and/or reducing the severity and/or reducing the occurrence of food allergies and related food allergy effects on health.
- a synthetic nutritional composition i.e. as a synthetic nutritional agent
- the invention is also related to the use of a food product comprising an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least at least on sialylated oligosaccharide, and at least one fucosylated oligosaccharide, as a synthetic nutritional composition (i.e. as a synthetic nutritional agent), for the enhancement of the oral tolerance to allergens.
- a food product comprising an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least at least on sialylated oligosaccharide, and at least one fucosylated oligosaccharide, as a synthetic nutritional composition (i.e. as a synthetic nutritional agent), for the enhancement of the oral tolerance to allergens.
- the food product is a supplement, preferably provided in the form of unit doses.
- the food product according to the invention is for use in infants and young children.
- the compositions and uses as per the present invention are particularly suited for infants and children at risk of allergies, having a family history of allergies, or having already experienced some episodes of allergies (especially respiratory allergies or skin allergies).
- the composition and uses of the invention apply to teenagers or adults at risk of allergies or having experiences episodes of allergies (especially respiratory allergies or skin allergies).
- the invention encompasses the use of the claimed composition in a population of infants or young children and for alleviating the symptoms of allergies or reducing the risk of allergies later in life.
- the food product may be prepared in any suitable manner known in the art according to the type of product, and the oligosaccharide mixture of the invention may be added to the product at an appropriate stage during the manufacturing process.
- an infant formula may be prepared by blending together the protein source, together with any carbohydrates other than lactose, and the fat source in appropriate proportions.
- Emulsifiers may be added if desired. Vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
- the liquid mixture may then be thermally treated to reduce bacterial loads, by rapidly heating the liquid mixture to a temperature in the range between about 80°C and about 150°C for a duration between about 5 seconds and about 5 minutes, for example.
- This may be carried out by means of steam injection, an autoclave or a heat exchanger, for example a plate heat exchanger.
- the liquid mixture may be cooled to between about 60°C and about 85°C for example by flash cooling.
- the liquid mixture may then be again homogenised, for example in two stages between about 10 MPa and about 30 MPa in the first stage and between about 2 MPa and about 10 M Pa in the second stage.
- the homogenised mixture may then be further cooled to add any heat sensitive components, such as vitamins and minerals.
- the pH and solids content of the homogenised mixture are conveniently adjusted at this point.
- the homogenised mixture is transferred to a suitable drying apparatus such as a spray dryer or freeze dryer and converted to powder.
- the powder should have a moisture content of less than about 5% by weig ht.
- the N-acetyl-lactosamine, sialylated oligosaccharide(s) and fucosylated oligosaccharide(s) may be added at this stage by dry-mixing along with the probiotic bacterial strain(s) if used, or by blending them in a syrup form of crystals, along with the probiotic bacterial strain(s) if used, and spray-dry (or freeze -dry).
- the oligosaccharide mixture of the invention is preferably added directly to infant formula by dry mixing. However, if it has been prepared from an animal milk, for example as described below, it may be convenient to add the oligosaccharide mixture without first removing all the lactose.
- the final concentration of the oligosaccharide mixture in the young child or infant food product or formula is preferably from 0.3 to 4%, preferably from 0.75 to 1.54% by weight of dry matter. This corresponds to a concentration of from 0.2 to 5 grams per litre of reconstituted formula, preferably from 1 to 2 g/l .
- the formula or feed containing the oligosaccharide mixture of the invention is given to the infant each time it is fed.
- the oligosaccharide mixtures may be added to wet infant or adult food products by wet m ixi ng .
- the m ixture may be added to the infant formula at concentrations of from about 0.2 to about 5 grams of oligosaccharides per litre of product.
- these amounts should not be construed as limitative and should be adapted to the target population, for example based on the weight and age of the young child or infant, or the health of the specific population.
- the oligosaccharide blend is preferably added in the form of syrup.
- the syrup may contain up to 80% total solids, but this should not be limitative.
- the oligosaccharide mixtures of the invention can be incorporated into healthcare nutrition products and nutritional products for the elderly.
- Such food products may include milk, yoghurt, curd, cheese, ice cream , among others.
- Such food products include also oral food supplement, and enteral nutrition preparations or exam ple for tu be feeding administration.
- a food product such as an infant formula may comprise one or more further oligosaccharides which are added separately.
- Vitamin E (mg TE) 0.8 5.4
- Vitamin B1 (mg) 0.07 0.47
- Vitamin B2 (mg) 0.15 1.0
- Vitamin B6 (mg) 0.075 0.50
- Vitamin B12 ⁇ g 0.3 2
- providing a nutritional composition with a secured level of the specific oligosaccharides blend together with hydrolyzed proteins may help reestablishing the natural balance of bacteria in the intestinal tract of infants and/or thus positively influence the health status in regards to the prevention and/or treatment of skin conditions and skin diseases, preferably atopic dermatitis.
- the findings demonstrate the usefulness of the invention.
- Bifidobacterium longum subsp infantis was grown anaerobic in API growth medium supplemented either with 1% (w/v) glucose, or 1% (w/v) 2' fucosyllactose (2FL) or 1 % (w/v) lacto-N-neotetrasose (LNnT) or 1 % (w/v) 6'sialyllactose (6SL) or 1% (w/v) of a combination of equal amounts of 2FL, LNnT and 6SL. Each overnight culture was diluted to have a starting OD600 of 0.1 in DMEM (Dulbeccos modified Eagle Medium) containing as a carbon source 0.1% glucose.
- DMEM Dynamiconitrate
- This medium was used without any further carbohydrate supplement or with additional 1% (w/v) glucose, or 1% (w/v) 2'fucosyllactose (2FL) or 1% (w/v) lacto-N-neotetrasose (LNnT) or 1% (w/v) 6'sialyllactose (6SL) or 1% (w/v) of a combination of equal amounts of 2FL, LNnT and 6SL. Conditioning of DMEM media was thus done at 37°C anaerobic.
- an oligosaccharide blend composed of equal parts of a fucoslylated oligosaccharide (e.g. 2'FL), an N-acetylated oligosaccharide (e.g. LNnT) and a sialylated oligosaccharide (e.g. 6SL) significantly increased metabolic activity of a lactic acid bacterium (e.g. bifidobacterium), as seen by the formation of acetate ( Figure 1).
- a fucoslylated oligosaccharide e.g. 2'FL
- N-acetylated oligosaccharide e.g. LNnT
- sialylated oligosaccharide e.g. 6SL
- the oligosaccharide blend also stimulated growth of the bacterium (figure 2).
- Study model 2 Retrospective epidemiologic analysis of breast milk samples and occurrence of allergic diseases up to the age of 2 years
- Figure 3 illustrates the experimental results showing in caesarean born children absence (no) and occurrence (yes) of (A) allergic diseases, (B) atopic allergies, (C) atopic eczema up to 2 years of age. Plotted are amounts of a specific oligosaccharide blend measured in breast milk. Here the represented oligosaccharide blend is the sum of 2'fucosyllactose (2FL), Lacto-N-neotetraose (LNnT) and 6' siaylllactose (6SL). (Statistical significance is indicated)
- Figure 4 illustrates the experimental results showing in caesarean born children absence (no) and occurrence (yes) of (A) allergic diseases, (B) atopic allergies, (C) atopic eczema up to 2 years of age. Plotted are amounts of a specific oligosaccharide blend measured in breast milk.
- the represented oligosaccharide blend is the sum of 2'fucosyllactose (2FL), Lacto-N-neotetraose (LNnT), Lacto-N-tetraose (LNT), 6'sialyllactose (6SL) and 3'siaylllactose (3SL). (Statistical significance is indicated)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/988,984 US9854826B2 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
RU2013128595/13A RU2581731C2 (en) | 2010-11-23 | 2011-11-21 | Mixture of oligosaccharides and food product containing said mixture, in particular nutritional mixture for infant feeding |
EP11784696.4A EP2642876B1 (en) | 2010-11-23 | 2011-11-21 | Food product comprising an oligosaccharide mixture and hydrolysed proteins used for reducind food allergies |
BR112013012599A BR112013012599A2 (en) | 2010-11-23 | 2011-11-21 | oligosaccharide mixture and food product comprising this mixture, especially infant formula |
CN201180056455.XA CN103582426A (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
CA2818015A CA2818015A1 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
SG2013038203A SG190325A1 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
ES11784696T ES2928210T3 (en) | 2010-11-23 | 2011-11-21 | Food product comprising a mixture of oligosaccharides and hydrolyzed proteins used to reduce food allergies |
AU2011333861A AU2011333861C1 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
MX2013005862A MX363737B (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula. |
IL226408A IL226408A0 (en) | 2010-11-23 | 2013-05-16 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
ZA2013/04644A ZA201304644B (en) | 2010-11-23 | 2013-06-21 | Oligosaccharide mixture and food product comprising this mixture,especially infant formula |
US15/838,551 US10716321B2 (en) | 2010-11-23 | 2017-12-12 | Oligosaccharide mixture and food product comprising same |
PH12019500518A PH12019500518A1 (en) | 2010-11-23 | 2019-03-11 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10192231A EP2454948A1 (en) | 2010-11-23 | 2010-11-23 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
EP10192231.8 | 2010-11-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/988,984 A-371-Of-International US9854826B2 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
US15/838,551 Division US10716321B2 (en) | 2010-11-23 | 2017-12-12 | Oligosaccharide mixture and food product comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012069416A1 true WO2012069416A1 (en) | 2012-05-31 |
Family
ID=44201036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/070566 WO2012069416A1 (en) | 2010-11-23 | 2011-11-21 | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
Country Status (18)
Country | Link |
---|---|
US (2) | US9854826B2 (en) |
EP (2) | EP2454948A1 (en) |
CN (1) | CN103582426A (en) |
AU (1) | AU2011333861C1 (en) |
BR (1) | BR112013012599A2 (en) |
CA (1) | CA2818015A1 (en) |
CL (1) | CL2013001470A1 (en) |
ES (1) | ES2928210T3 (en) |
IL (1) | IL226408A0 (en) |
MX (2) | MX363737B (en) |
MY (1) | MY163082A (en) |
PH (1) | PH12019500518A1 (en) |
PT (1) | PT2642876T (en) |
RU (1) | RU2581731C2 (en) |
SG (1) | SG190325A1 (en) |
TW (1) | TW201242518A (en) |
WO (1) | WO2012069416A1 (en) |
ZA (1) | ZA201304644B (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
WO2015071131A1 (en) * | 2013-11-15 | 2015-05-21 | Nestec S.A. | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by c-section |
WO2015086789A1 (en) | 2013-12-13 | 2015-06-18 | Nestec S.A. | Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions |
WO2015154660A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and, nutritional systems comprising them |
WO2015154665A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154662A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
US20150320778A1 (en) * | 2012-12-18 | 2015-11-12 | Abbott Laboratories | Human milk oligosaccharides to ameliorate symptoms of stress |
US20150342974A1 (en) * | 2012-12-18 | 2015-12-03 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
WO2016157108A1 (en) * | 2015-03-31 | 2016-10-06 | Glycom A/S | Mixtures of human milk oligosaccharides comprising 3 '-o-sialyllactose |
AU2011340882B2 (en) * | 2010-11-23 | 2016-10-20 | Société des Produits Nestlé S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
WO2016184880A1 (en) | 2015-05-19 | 2016-11-24 | Nestec S.A. | Kit-of-parts to identify mother's milk missing fucosyltransferase-2 dependent glycans and feeding doses with said glycans |
WO2017102715A1 (en) | 2015-12-14 | 2017-06-22 | Nestec S.A. | Compositions and their use |
WO2017167896A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising minerals and their use |
WO2017167420A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising vitamins and their use |
WO2017167898A2 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions and their use |
WO2017167416A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising phospholipid and their use |
WO2017167415A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising fatty acids and their use |
WO2017167895A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising choline and their use |
WO2017167418A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Nutritional compositions and their use |
WO2018215406A1 (en) | 2017-05-24 | 2018-11-29 | Nestec S.A. | A nutritional composition for use to enhance attention and/or reduce impulsivity |
WO2019038159A1 (en) | 2017-08-22 | 2019-02-28 | Nestec S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2019038160A1 (en) | 2017-08-22 | 2019-02-28 | Nestec S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them |
WO2019122116A1 (en) | 2017-12-22 | 2019-06-27 | Societe Des Produits Nestle S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them |
WO2019122123A1 (en) | 2017-12-22 | 2019-06-27 | Societe Des Produits Nestle S.A. | Gender specific synthetic nutritional compositions comprising lycopene and nutritional systems comprising them |
EP3331534B1 (en) | 2015-08-04 | 2019-12-18 | Société des Produits Nestlé S.A. | Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants |
US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
WO2020064678A1 (en) | 2018-09-25 | 2020-04-02 | Société des Produits Nestlé S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2020064680A1 (en) | 2018-09-25 | 2020-04-02 | Société des Produits Nestlé S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them. |
WO2020089291A1 (en) | 2018-10-30 | 2020-05-07 | Société des Produits Nestlé S.A. | Nutritional compositions, their use in reducing metabolic stress and method of reducing metabolic stress |
WO2020127409A1 (en) | 2018-12-19 | 2020-06-25 | Société des Produits Nestlé S.A. | Composition for preventing or reducing transepidermal water loss and improving skin barrier function |
EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
WO2020178362A1 (en) | 2019-03-05 | 2020-09-10 | Société des Produits Nestlé S.A. | A nutritional composition for use to enhance executive function |
US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
WO2022129518A1 (en) | 2020-12-18 | 2022-06-23 | Société des Produits Nestlé S.A. | Synthetic nutritional compositions tailored for chinese infants |
EP2642876B1 (en) | 2010-11-23 | 2022-07-13 | Société des Produits Nestlé S.A. | Food product comprising an oligosaccharide mixture and hydrolysed proteins used for reducind food allergies |
US11464793B2 (en) | 2010-12-31 | 2022-10-11 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11524019B2 (en) | 2017-08-21 | 2022-12-13 | Glycom A/S | Synthetic composition for reducing allergy symptoms |
US11701376B2 (en) | 2010-12-31 | 2023-07-18 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201603856PA (en) | 2010-12-31 | 2016-07-28 | Abbott Lab | Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides |
CN103379908B (en) | 2010-12-31 | 2020-02-14 | 雅培制药有限公司 | Methods of reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents |
CN107595860A (en) | 2011-07-22 | 2018-01-19 | 雅培制药有限公司 | For preventing injury of gastrointestinal tract and/or promoting the galactooligosaccharide of intestines and stomach reparation |
MY169326A (en) | 2011-08-29 | 2019-03-21 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
MX2016006060A (en) | 2013-11-15 | 2016-08-03 | Nestec Sa | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children. |
RU2016123464A (en) | 2013-11-15 | 2017-12-20 | Нестек С.А. | COMPOSITIONS FOR APPLICATION FOR PREVENTION OR TREATMENT OF NECRETIZING ENTEROCOLITIS IN CHILDREN OF BREAST OR YOUNGEST AGENCIES BORN BY CESARA SECTION |
CA2942732C (en) | 2014-04-08 | 2023-01-03 | Abbott Laboratories | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides |
JP2017520267A (en) * | 2014-07-14 | 2017-07-27 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Biotechnological production of LNT, LNnT and their fucosylated derivatives |
MX2017005260A (en) * | 2014-10-24 | 2018-01-30 | Evolve Biosystems Inc | Activated bifidobacteria and methods of use thereof. |
US11040049B2 (en) | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
US11040050B2 (en) * | 2014-10-29 | 2021-06-22 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
CN115364113A (en) | 2014-10-29 | 2022-11-22 | 格礼卡姆股份公司 | Synthetic compositions and methods for treating irritable bowel syndrome |
US20200138838A1 (en) * | 2014-10-29 | 2020-05-07 | Glycom A/S | Composition comprising hmss/hmos and use thereof |
US20160243139A1 (en) * | 2014-10-29 | 2016-08-25 | Glycom A/S | Composition comprising HMSs/HMOs and use thereof |
WO2016066735A1 (en) * | 2014-10-31 | 2016-05-06 | Nestec S.A. | Composition comprising fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition |
EP3264921A1 (en) * | 2015-03-05 | 2018-01-10 | Nestec S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
ES2759556T3 (en) | 2015-12-15 | 2020-05-11 | Nestle Sa | Oligosaccharic mixture from human milk |
US11096410B2 (en) | 2016-01-26 | 2021-08-24 | Societe Des Produits Nestle S.A. | Composition for use in the prevention and/or treatment of skin conditions and skin diseases |
AU2017213085B2 (en) * | 2016-01-26 | 2021-07-01 | Société des Produits Nestlé S.A. | Compositions comprising 2FL and LNnT to control food intake and growth in infants or young children |
ES2911377T3 (en) | 2016-01-26 | 2022-05-19 | Nestle Sa | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat allergies |
EP3490567A4 (en) | 2016-07-28 | 2020-03-18 | Fonterra Co-Operative Group Limited | Dairy product and process |
RU2742510C2 (en) * | 2016-09-07 | 2021-02-08 | Сосьете Де Продюи Нестле С.А. | Nutritional composition for infants and/or young children containing oligosaccharides |
US11253530B2 (en) | 2017-05-09 | 2022-02-22 | Societe Des Produits Nestle S.A. | Synergistic production of butyrate associated with the complexity of HMOS blend for use in infants or young children for health purposes |
AU2018390181A1 (en) * | 2017-12-22 | 2020-05-28 | Societe Des Produits Nestle S.A. | Compositions for use in the reduction of nociception in infants and young children |
CN111683666A (en) * | 2017-12-22 | 2020-09-18 | 格礼卡姆股份公司 | Compositions comprising HMOs for preventing or reducing nociception |
JP2021524238A (en) * | 2018-05-23 | 2021-09-13 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | Production of oligosaccharides |
CN109731000B (en) * | 2018-12-25 | 2021-02-19 | 东北农业大学 | Application of 2' -fucosyllactose |
US20240138460A1 (en) * | 2019-10-17 | 2024-05-02 | Societe Des Produits Nestle S.A. | Extensively hydrolysed infant formula |
BR112022008956A2 (en) * | 2019-12-06 | 2022-08-02 | Nestle Sa | COMPOSITIONS FOR USE IN REDUCTION OF PAIN AND/OR PERCEPTION OF PAIN IN BABIES AND SMALL CHILDREN |
AU2020399200A1 (en) * | 2019-12-11 | 2022-06-09 | Société des Produits Nestlé S.A. | Compositions for use in the reduction of nociception and other health benefits in infants and young children |
AU2020419435A1 (en) * | 2019-12-30 | 2022-05-26 | Société des Produits Nestlé S.A. | Infant formula |
JP7516053B2 (en) * | 2020-01-20 | 2024-07-16 | 森永乳業株式会社 | Composition, food and drink composition, nutritional composition and formula |
EP4228436A1 (en) * | 2020-10-16 | 2023-08-23 | Société des Produits Nestlé S.A. | Nutritional composition comprising human milk oligosaccharides |
CN114009510A (en) * | 2021-11-24 | 2022-02-08 | 北安宜品努卡乳业有限公司 | Hypoallergenic infant goat milk-based formula milk powder and preparation method thereof |
WO2024008851A1 (en) * | 2022-07-08 | 2024-01-11 | Société des Produits Nestlé S.A. | Uses of bifidobacterium longum transitional microorganism |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288637A (en) | 1990-04-16 | 1994-02-22 | The Trustees Of The University Of Pennsylvania | Apparatus for the synthesis of saccharide compositions |
WO1996010086A1 (en) | 1994-09-26 | 1996-04-04 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US6146670A (en) * | 1997-03-31 | 2000-11-14 | Abbott Laboratories | Nutritional formulations containing oligosaccharides |
US20030181401A1 (en) * | 2002-02-04 | 2003-09-25 | Kyowa Hakko Kogyo Co., Ltd. | Insulin secretion promoter |
JP2003292444A (en) * | 2002-02-04 | 2003-10-15 | Kyowa Hakko Kogyo Co Ltd | Insulin secretion promoting agent |
US20070275881A1 (en) * | 2003-12-05 | 2007-11-29 | Morrow Ardythe L | Oligosaccharide Compositions and Use Thereof in the Treatment of Infection |
US20090197806A1 (en) * | 2006-01-09 | 2009-08-06 | Morrow Ardythe L | Adiponectin for treatment of various disorders |
US20090305996A1 (en) * | 2006-03-10 | 2009-12-10 | N.V. Nutricia | Use of non-digestable sacharides for giving an infant the best start after birth |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040013787A1 (en) * | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
EP1926394B1 (en) | 2005-02-21 | 2020-02-19 | Société des Produits Nestlé S.A. | Oligosaccharide mixture |
US8287931B2 (en) * | 2005-06-30 | 2012-10-16 | Mead Johnson Nutrition Company | Nutritional composition to promote healthy development and growth |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
EP1993576B1 (en) | 2006-03-07 | 2015-10-21 | Nestec S.A. | Synbiotic mixture |
WO2008153377A1 (en) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
AU2008324105B2 (en) | 2007-11-08 | 2014-01-30 | Société des Produits Nestlé S.A. | Use of oligosaccharides containing N-acetyllactosamine for maturation of immune responses in neonates |
WO2009151315A1 (en) | 2008-06-13 | 2009-12-17 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
PL2453902T3 (en) | 2009-07-15 | 2014-01-31 | Nutricia Nv | Mixture of non-digestible oligosaccharides for stimulating the immune system |
EP2308498A1 (en) | 2009-09-30 | 2011-04-13 | Nestec S.A. | Administration of Bifidobacterium breve during infancy to prevent inflammation later in life |
ES2569241T5 (en) | 2010-01-19 | 2019-09-11 | Abbott Lab | A composition comprising Lactobacillus rhamnosus HN001 and prebiotics for use in the treatment of allergic lung disease |
EP2465508A1 (en) | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
EP2454948A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
-
2010
- 2010-11-23 EP EP10192231A patent/EP2454948A1/en not_active Withdrawn
-
2011
- 2011-11-21 MX MX2013005862A patent/MX363737B/en active IP Right Grant
- 2011-11-21 CN CN201180056455.XA patent/CN103582426A/en active Pending
- 2011-11-21 SG SG2013038203A patent/SG190325A1/en unknown
- 2011-11-21 WO PCT/EP2011/070566 patent/WO2012069416A1/en active Application Filing
- 2011-11-21 BR BR112013012599A patent/BR112013012599A2/en not_active Application Discontinuation
- 2011-11-21 EP EP11784696.4A patent/EP2642876B1/en active Active
- 2011-11-21 AU AU2011333861A patent/AU2011333861C1/en active Active
- 2011-11-21 CA CA2818015A patent/CA2818015A1/en not_active Abandoned
- 2011-11-21 RU RU2013128595/13A patent/RU2581731C2/en active
- 2011-11-21 US US13/988,984 patent/US9854826B2/en active Active
- 2011-11-21 ES ES11784696T patent/ES2928210T3/en active Active
- 2011-11-21 MY MYPI2013700800A patent/MY163082A/en unknown
- 2011-11-21 PT PT117846964T patent/PT2642876T/en unknown
- 2011-11-23 TW TW100142956A patent/TW201242518A/en unknown
-
2013
- 2013-05-16 IL IL226408A patent/IL226408A0/en unknown
- 2013-05-23 MX MX2019002953A patent/MX2019002953A/en unknown
- 2013-05-23 CL CL2013001470A patent/CL2013001470A1/en unknown
- 2013-06-21 ZA ZA2013/04644A patent/ZA201304644B/en unknown
-
2017
- 2017-12-12 US US15/838,551 patent/US10716321B2/en active Active
-
2019
- 2019-03-11 PH PH12019500518A patent/PH12019500518A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288637A (en) | 1990-04-16 | 1994-02-22 | The Trustees Of The University Of Pennsylvania | Apparatus for the synthesis of saccharide compositions |
WO1996010086A1 (en) | 1994-09-26 | 1996-04-04 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US6146670A (en) * | 1997-03-31 | 2000-11-14 | Abbott Laboratories | Nutritional formulations containing oligosaccharides |
US20030181401A1 (en) * | 2002-02-04 | 2003-09-25 | Kyowa Hakko Kogyo Co., Ltd. | Insulin secretion promoter |
JP2003292444A (en) * | 2002-02-04 | 2003-10-15 | Kyowa Hakko Kogyo Co Ltd | Insulin secretion promoting agent |
US20070275881A1 (en) * | 2003-12-05 | 2007-11-29 | Morrow Ardythe L | Oligosaccharide Compositions and Use Thereof in the Treatment of Infection |
US20090197806A1 (en) * | 2006-01-09 | 2009-08-06 | Morrow Ardythe L | Adiponectin for treatment of various disorders |
US20090305996A1 (en) * | 2006-03-10 | 2009-12-10 | N.V. Nutricia | Use of non-digestable sacharides for giving an infant the best start after birth |
Non-Patent Citations (5)
Title |
---|
GIBSON GR; ROBERFROID MB: "Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics", J NUTR., vol. 125, 1995, pages 1401 - 12, XP000972244 |
SALMINEN S; OUWEHAND A; BENNO Y. ET AL.: "Probiotics: how should they be defined", TRENDS FOOD SCI. TECHNOL., vol. 10, 1999, pages 107 - 10, XP055150446 |
THURL S ET AL: "Quantification of individual oligosaccharide compounds from human milk using high-pH anion-exchange chromatography", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 235, no. 2, 1 January 1996 (1996-01-01), pages 202 - 206, XP002439151, ISSN: 0003-2697, DOI: 10.1006/ABIO.1996.0113 * |
THURL S ET AL: "VARIATIONS OF NEUTRAL OLIGOSACCHARIDES AND LACTOSE IN HUMAN MILK DURING THE FEEDING", ZEITSCHRIFT FUER ERNAEHRUNGSWISSENSCHAFT, STEINKOPF VERLAG, DARMSTADT, DE, vol. 32, no. 41, 1 January 1993 (1993-01-01), pages 262 - 269, XP002071967, ISSN: 0044-264X, DOI: 10.1007/BF01611164 * |
WRODNIGG, T.M.; STUTZ, A.E., ANGEW. CHEM. INT. ED., vol. 38, 1999, pages 827 - 828 |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2642876B1 (en) | 2010-11-23 | 2022-07-13 | Société des Produits Nestlé S.A. | Food product comprising an oligosaccharide mixture and hydrolysed proteins used for reducind food allergies |
US9763465B2 (en) | 2010-11-23 | 2017-09-19 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
AU2011340882B2 (en) * | 2010-11-23 | 2016-10-20 | Société des Produits Nestlé S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
US11975014B2 (en) | 2010-12-31 | 2024-05-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
US11464793B2 (en) | 2010-12-31 | 2022-10-11 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11524018B2 (en) | 2010-12-31 | 2022-12-13 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11633412B2 (en) | 2010-12-31 | 2023-04-25 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11654156B2 (en) | 2010-12-31 | 2023-05-23 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11701376B2 (en) | 2010-12-31 | 2023-07-18 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US11109603B2 (en) | 2011-06-20 | 2021-09-07 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
US11771102B2 (en) | 2011-06-20 | 2023-10-03 | H.J. Heinz Company Brands Llc | Probiotic compositions and methods |
US20150342974A1 (en) * | 2012-12-18 | 2015-12-03 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
US20150320778A1 (en) * | 2012-12-18 | 2015-11-12 | Abbott Laboratories | Human milk oligosaccharides to ameliorate symptoms of stress |
WO2014100225A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
US10779550B2 (en) * | 2012-12-18 | 2020-09-22 | Abbott Laboratories | Human milk oligosaccharides to ameliorate symptoms of stress |
US11160817B2 (en) * | 2012-12-18 | 2021-11-02 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
CN105682664A (en) * | 2013-11-15 | 2016-06-15 | 雀巢产品技术援助有限公司 | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by c-section |
RU2697650C1 (en) * | 2013-11-15 | 2019-08-16 | Сосьете Де Продюи Нестле С.А. | Compositions for preventing or treating allergies in infants born or fed by non-secretory mothers by providing fucosylated oligosaccharides, particularly infants at risk of or born by cesarean section |
US10758555B2 (en) | 2013-11-15 | 2020-09-01 | Societe Des Produits Nestle S.A. | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section |
WO2015071131A1 (en) * | 2013-11-15 | 2015-05-21 | Nestec S.A. | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by c-section |
US11135233B2 (en) | 2013-11-19 | 2021-10-05 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
WO2015086789A1 (en) | 2013-12-13 | 2015-06-18 | Nestec S.A. | Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions |
WO2015154662A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154660A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and, nutritional systems comprising them |
WO2015154665A1 (en) | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
US11173171B2 (en) | 2015-03-31 | 2021-11-16 | Glycom A/S | Mixtures of human milk oligosaccharides comprising 3′-O-sialyllactose |
US10588917B2 (en) | 2015-03-31 | 2020-03-17 | Glycom A/S | Mixtures of human milk oligosaccharides comprising 3 ′-O-sialyllactose |
WO2016157108A1 (en) * | 2015-03-31 | 2016-10-06 | Glycom A/S | Mixtures of human milk oligosaccharides comprising 3 '-o-sialyllactose |
EP3298404B1 (en) * | 2015-05-19 | 2022-04-20 | Société des Produits Nestlé S.A. | Kit-of-parts to identify mother's milk missing fucosyltransferase-2 dependent glycans |
WO2016184880A1 (en) | 2015-05-19 | 2016-11-24 | Nestec S.A. | Kit-of-parts to identify mother's milk missing fucosyltransferase-2 dependent glycans and feeding doses with said glycans |
EP3331534B1 (en) | 2015-08-04 | 2019-12-18 | Société des Produits Nestlé S.A. | Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants |
EP4205561A1 (en) | 2015-12-14 | 2023-07-05 | Société des Produits Nestlé S.A. | Nutritional composition and infant formula for promoting myelination of the brain |
WO2017102715A1 (en) | 2015-12-14 | 2017-06-22 | Nestec S.A. | Compositions and their use |
WO2017102712A1 (en) | 2015-12-14 | 2017-06-22 | Nestec S.A. | Nutritional composition and infant formula for promoting myelination of the brain |
EP4233904A2 (en) | 2015-12-14 | 2023-08-30 | Société des Produits Nestlé S.A. | Compositions and their use |
EP4233875A2 (en) | 2015-12-14 | 2023-08-30 | Société des Produits Nestlé S.A. | Nutritional composition an infant formula for prmoting de novo myelination |
EP4233855A2 (en) | 2015-12-14 | 2023-08-30 | Société des Produits Nestlé S.A. | Nutritional composition and infant formula for promoting myelination of the brain |
EP4233860A2 (en) | 2015-12-14 | 2023-08-30 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
WO2017167896A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising minerals and their use |
WO2017167418A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Nutritional compositions and their use |
WO2017167899A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising fatty acids and their use |
WO2017167897A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising phospholipid and their use |
WO2017167895A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising choline and their use |
WO2017167415A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising fatty acids and their use |
WO2017167416A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising phospholipid and their use |
WO2017167898A2 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions and their use |
WO2017167420A1 (en) | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising vitamins and their use |
WO2018215406A1 (en) | 2017-05-24 | 2018-11-29 | Nestec S.A. | A nutritional composition for use to enhance attention and/or reduce impulsivity |
US11524019B2 (en) | 2017-08-21 | 2022-12-13 | Glycom A/S | Synthetic composition for reducing allergy symptoms |
WO2019038160A1 (en) | 2017-08-22 | 2019-02-28 | Nestec S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them |
WO2019038159A1 (en) | 2017-08-22 | 2019-02-28 | Nestec S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2019122116A1 (en) | 2017-12-22 | 2019-06-27 | Societe Des Produits Nestle S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them |
WO2019122123A1 (en) | 2017-12-22 | 2019-06-27 | Societe Des Produits Nestle S.A. | Gender specific synthetic nutritional compositions comprising lycopene and nutritional systems comprising them |
WO2020064678A1 (en) | 2018-09-25 | 2020-04-02 | Société des Produits Nestlé S.A. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2020064680A1 (en) | 2018-09-25 | 2020-04-02 | Société des Produits Nestlé S.A. | Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them. |
WO2020089291A1 (en) | 2018-10-30 | 2020-05-07 | Société des Produits Nestlé S.A. | Nutritional compositions, their use in reducing metabolic stress and method of reducing metabolic stress |
WO2020127409A1 (en) | 2018-12-19 | 2020-06-25 | Société des Produits Nestlé S.A. | Composition for preventing or reducing transepidermal water loss and improving skin barrier function |
WO2020178362A1 (en) | 2019-03-05 | 2020-09-10 | Société des Produits Nestlé S.A. | A nutritional composition for use to enhance executive function |
WO2022129518A1 (en) | 2020-12-18 | 2022-06-23 | Société des Produits Nestlé S.A. | Synthetic nutritional compositions tailored for chinese infants |
Also Published As
Publication number | Publication date |
---|---|
IL226408A0 (en) | 2013-07-31 |
TW201242518A (en) | 2012-11-01 |
BR112013012599A2 (en) | 2016-07-19 |
ZA201304644B (en) | 2018-12-19 |
AU2011333861A1 (en) | 2013-06-06 |
SG190325A1 (en) | 2013-06-28 |
ES2928210T3 (en) | 2022-11-16 |
RU2581731C2 (en) | 2016-04-20 |
CN103582426A (en) | 2014-02-12 |
CA2818015A1 (en) | 2012-05-31 |
US9854826B2 (en) | 2018-01-02 |
US20130251844A1 (en) | 2013-09-26 |
EP2642876A1 (en) | 2013-10-02 |
US20180110253A1 (en) | 2018-04-26 |
AU2011333861B2 (en) | 2015-09-03 |
MX2013005862A (en) | 2013-07-05 |
CL2013001470A1 (en) | 2013-12-27 |
EP2454948A1 (en) | 2012-05-23 |
AU2011333861C1 (en) | 2020-11-12 |
MY163082A (en) | 2017-08-15 |
PH12019500518A1 (en) | 2020-09-14 |
MX2019002953A (en) | 2019-10-21 |
MX363737B (en) | 2019-04-01 |
US10716321B2 (en) | 2020-07-21 |
RU2013128595A (en) | 2014-12-27 |
PT2642876T (en) | 2022-10-17 |
EP2642876B1 (en) | 2022-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10716321B2 (en) | Oligosaccharide mixture and food product comprising same | |
EP2643004B1 (en) | Oligosaccharide composition for treating skin diseases | |
US9161563B2 (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
AU2011340881B2 (en) | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases | |
US9763465B2 (en) | Oligosaccharide composition for treating acute respiratory tract infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11784696 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2818015 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500971 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 226408 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13988984 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001470 Country of ref document: CL Ref document number: 2011784696 Country of ref document: EP Ref document number: MX/A/2013/005862 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011333861 Country of ref document: AU Date of ref document: 20111121 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201307758 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2013128595 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013012599 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013012599 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130521 |